Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Other financing activities (2017 - 2025)

Sutro Biopharma (STRO) has disclosed Other financing activities for 9 consecutive years, with $66000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 175.0% to $66000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $332000.0 through Dec 2025, down 34.77% year-over-year, with the annual reading at $332000.0 for FY2025, 34.77% down from the prior year.
  • Other financing activities hit $66000.0 in Q4 2025 for Sutro Biopharma, up from $25000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $580000.0 in Q3 2021 to a low of -$135.7 million in Q4 2023.
  • Historically, Other financing activities has averaged -$7.0 million across 5 years, with a median of $61000.0 in 2025.
  • Biggest five-year swings in Other financing activities: crashed 91.38% in 2022 and later skyrocketed 516.67% in 2024.
  • Year by year, Other financing activities stood at -$84000.0 in 2021, then surged by 159.52% to $50000.0 in 2022, then tumbled by 271536.0% to -$135.7 million in 2023, then surged by 100.02% to $24000.0 in 2024, then soared by 175.0% to $66000.0 in 2025.
  • Business Quant data shows Other financing activities for STRO at $66000.0 in Q4 2025, $25000.0 in Q3 2025, and $61000.0 in Q2 2025.